This Article Abstract Full Text (PDF) All Versions of this Article: 111/14/1822    most recent 01.CIR.0000160854.75779.E8v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Eitzman, D. T. Articles by Ginsburg, D. Search for Related Content PubMed PubMed Citation Articles by Eitzman, D. T. Articles by Ginsburg, D. Pubmed/NCBI databases Gene GEO Profiles HomoloGene UniGene Substance via MeSH Related Collections Arterial thrombosis Coagulation Thrombin Other Vascular biology Animal models of human disease Pathophysiology Genetically altered mice Related Articles

(Circulation. 2005;111:1822-1825.)
© 2005 American Heart Association, Inc.

Vascular Medicine

Homozygosity for Factor V Leiden Leads to Enhanced Thrombosis and Atherosclerosis in Mice

Daniel T. Eitzman, MD; Randal J. Westrick, BSc; Yuechun Shen, MD; Peter F. Bodary, PhD; Shufang Gu, PhD; Sara L. Manning, BSc; Sarah L. Dobies, BSc; David Ginsburg, MD

From the Divisions of Cardiology (D.T.E., Y.S., P.F.B., S.G.) and Molecular Medicine and Genetics (D.G.); the Department of Internal Medicine, Department of Human Genetics (R.J.W., D.G.); the Life Sciences Institute (S.L.D., D.G.); and the Howard Hughes Medical Institute (S.L.M., D.G.), University of Michigan Medical Center, Ann Arbor.

Reprint requests to Daniel T. Eitzman, MD, University of Michigan Medical Center, MSRB III, Room 7301, 1150 Medical Center Dr, Ann Arbor, MI 48109-0644. E-mail deitzman{at}umich.edu

Received October 20, 2004; revision received December 22, 2004; accepted January 10, 2005.

	Abstract

Top Abstract Introduction Methods Results Discussion References

 
Background— Activated protein C resistance due to factor V Leiden (FVL) is a common genetic risk factor for venous thrombosis in humans. Although the impact of FVL on the development of venous thrombosis is well established, its effect on arterial thrombosis and atherosclerosis is controversial.

Methods and Results— To determine the effect of the FVL mutation on arterial thrombosis in the mouse, wild-type (Fv^+/+), heterozygous FVL (Fv^Q/+), and homozygous FVL (Fv^Q/Q) mice underwent photochemical carotid arterial injury to induce occlusive thrombosis. Fv^Q/Q mice formed occlusive thromboses 27±3 minutes (n=7) after the onset of injury, which was significantly shorter than that observed for Fv^+/+ mice (56±7 minutes, n=9, P<0.01), whereas Fv^Q/+ mice (41±7 minutes, n=5) were intermediate (P=0.5, compared with Fv^+/+). To determine the source of FVL relevant to the enhanced vascular thrombosis, bone marrow transplantation experiments were performed between Fv^+/+ and Fv^Q/Q mice. Fv^Q/Q mice transplanted with Fv^+/+ bone marrow formed occlusive thromboses at 35±5 minutes (n=7, P<0.05 compared with Fv^+/+ mice), whereas Fv^+/+ mice transplanted with Fv^Q/Q bone marrow occluded at 59±7 minutes (n=6, P<0.001 compared with Fv^Q/Q mice). To assess the effect of the FVL mutation on the development of atherosclerosis, Fv^Q/Q mice were crossed with the atherosclerosis-prone apolipoprotein E (ApoE)–deficient strain (ApoE^–/–) to generate Fv^Q/Q,ApoE^–/– mice. By 52 weeks of age, Fv^Q/Q,ApoE^–/– mice (n=8) had developed more aortic atherosclerosis (40±6% lesion area) compared with Fv^+/+,ApoE^–/– mice (15±3% lesion area; n=12, P<0.02).

Conclusions— In conclusion, homozygosity for the FVL mutation in mice leads to enhanced arterial thrombosis and atherosclerosis. The source of the FVL leading to accelerated thrombosis appears to be circulating, non–platelet-derived plasma FVL.

Key Words: atherosclerosis • coagulation • fibrinogen • thrombosis

	Introduction

Top Abstract Introduction Methods Results Discussion References

 
Factor V Leiden (FVL), a missense mutation in the factor V gene resulting in the replacement of arginine at amino acid position 506 by glutamine, is found in 20% to 50% of patients presenting with venous thrombosis^1–3; however, the role of FVL in arterial thrombosis and atherosclerosis is controversial.^4–9 The risk of the homozygous FVL state, in particular, is difficult to ascertain because of its low prevalence.

See p 1733

The relevant source of FVL in vascular thrombosis is also unclear. In both humans and mice, there are distinct platelet and plasma pools of factor V. The origin of platelet factor V in humans appears to result from the plasma compartment,¹⁰ whereas mouse platelet factor V is derived from synthesis within the megakaryocyte.^11,12 Although the biosynthetic origins are different, the relative sizes of the 2 pools in mice and humans are similar.¹¹ Thus, the mouse may serve as a particularly useful model to dissect the relative contribution of these pools toward vascular thrombosis.

To test the hypothesis that the FVL mutation will affect arterial thrombosis and atherosclerosis, mice with varying patterns of FVL expression were studied in a carotid artery thrombosis model and crossed with atherosclerosis-prone, apolipoprotein E (ApoE)–deficient mice.

	Methods

Top Abstract Introduction Methods Results Discussion References

 
Mice
Generation of mice carrying the murine homologue of the FVL mutation has been previously described.¹³ These mice were backcrossed to C57BL/6J mice (Jackson Labs, Bar Harbor, Me) for at least 8 generations before use in thrombosis and atherosclerosis experiments. The ApoE-deficient mice were also obtained from Jackson Labs and were backcrossed to C57BL/6J for >10 generations before crossbreeding to FVL mice. Genotyping for FVL and ApoE was performed by polymerase chain reaction (PCR) analysis of tail DNA with the primers previously described.^13,14 After weaning, at 3 weeks of age, mice were fed standard chow (laboratory rodent diet No. 5001, TestDiet). At 7 weeks of age, one group of mice was switched to Western chow (TD 88137, Teklad) for atherosclerosis experiments.

Carotid Arterial Thrombosis
Eight-week-old, male, wild-type (Fv^+/+), FVL heterozygous (Fv^Q/+), and FVL homozygous (Fv^Q/Q) mice were subjected to photochemical injury of the right carotid artery by the application of rose bengal as previously described.¹⁵ Flow in the vessel was monitored until occlusive thrombosis occurred, defined as cessation of flow for at least 1 minute.

Bone Marrow Transplantation
Bone marrow transplantations were performed similarly to previously described methods.^11,16 Six-week-old, male Fv^+/+ and Fv^Q/Q mice were irradiated with 1300 rads followed by tail vein injection of RPMI containing 5x10⁶ fetal liver cells derived from Fv^+/+ or Fv^Q/Q donors. Control mice were irradiated but received only tail vein injection with medium. These control mice died 1 to 2 weeks after irradiation, consistent with engraftment in the surviving mice. Using an identical transplantation protocol in similar mice with the same genetic background, we have consistently observed complete engraftment by PCR analysis.¹¹

Analysis of Atherosclerotic Lesions in ApoE-Deficient Mice
At 19, 34, and 52 weeks of age, mice were perfusion fixed with zinc formalin under intraperitoneal pentobarbital anesthesia (100 mg/kg). For quantification of surface area occupied by atherosclerosis, the aorta and carotid arteries were stained with oil red O and then subjected to quantitative morphometry as previously described.¹⁷

Fibrin Immunostaining
Fibrin(ogen) immunostaining was performed with a goat anti-mouse fibrin(ogen) polyclonal antibody (Accurate Chemical and Scientific Corp). The primary antibody was detected with a biotin-labeled rabbit anti-goat IgGFc (Chemicon International, Inc). Aortic atherosclerotic lesions were graded for fibrin deposition by an observer who was blinded to the genotype of the mice by using a scale from 1 to 10, with each number representing a percent area of lesion staining for fibrin(ogen) (ie, 1=1% to 10%, 2=11% to 20%, 3=21% to 30%, etc).

Cholesterol Measurement
Serum obtained from retro-orbital bleeding was used to measure cholesterol with a commercial cholesterol kit from Wako Chemicals Inc.

Statistical Analysis
The statistical significance of differences in time to occlusion and atherosclerosis surface area between the various groups was determined by the Student 2-tailed t test when only 2 groups were being compared and by 1-way ANOVA (followed by pairwise post hoc comparison) when >2 experimental groups were included in the analysis. A probability value <0.05 was considered significant.

	Results

Top Abstract Introduction Methods Results Discussion References

 
Effect of FVL on Development of Occlusive Thrombosis After Carotid Injury
To examine the contribution of FVL to the development of occlusive thrombosis after carotid injury, 8-week-old mice were subjected to photochemical injury of the right mid-common carotid artery. The mean time to occlusion in Fv^Q/Q mice (n=7) was significantly shorter than that observed in Fv^+/+ (n=9) mice (Figure 1). Times to occlusion in Fv^Q/+ mice (n=5) were intermediate but not significantly different from those for Fv^+/+ or Fv^Q/Q mice.

View larger version (15K): [in this window] [in a new window]   Figure 1. Effect of FVL on arterial thrombosis. After onset of photochemical carotid injury, mice homozygous for FVL mutation (Q/Q) formed occlusive thrombi in shorter time period compared with wild-type (+/+) mice, whereas heterozygous (Q/+) mice were intermediate (NS). Bone marrow transplantation from Fv+/+ to FvQ/Q mice (+/+ to Q/Q) and from FvQ/Q to Fv+/+ mice (Q/Q to +/+) did not significantly alter recipient phenotype but was different from donor phenotype. *P<0.01 compared with Fv+/+ mice, ^P<0.05 compared with Fv+/+ mice, #P<0.001 compared with FvQ/Q mice. All other statistical comparisons between groups were not significant (NS).

To determine whether the source of the FVL affecting vascular thrombosis after arterial injury was derived from platelets or plasma, bone marrow transplantation was performed between Fv^+/+ and Fv^Q/Q mice. Fv^+/+ mice (n=6) that received marrow from Fv^Q/Q donors formed occlusive thrombosis in a time period similar to that of Fv^+/+ nontransplanted mice and significantly longer than in Fv^Q/Q mice. Fv^Q/Q mice (n=7) that received marrow from Fv^+/+ mice occluded in a time period similar to Fv^Q/Q nontransplanted mice but significantly shorter than in Fv^+/+ mice (Figure 1).

Effect of FVL on the Development of Atherosclerosis
To determine the effect of FVL on the development of atherosclerosis, groups of Fv^+/+,ApoE^–/–, Fv^Q/+,ApoE^–/–, and Fv^Q/Q,ApoE^–/– mice were euthanized at different ages. Group 1 (Fv^+/+,ApoE^–/– [n=4], Fv^Q/+,ApoE^–/– [n=6], and Fv^Q/Q,ApoE^–/– [n=4]) was started on a Western chow diet at 7 weeks of age and then euthanized at 19 weeks. With this protocol, no significant differences in atherosclerosis were observed among the 3 genotypes (Figure 2a). Because high-fat feeding greatly accelerates the progression of atherosclerosis, it is possible that relevant genetic modifiers of atherosclerosis could be overwhelmed under these circumstances. Therefore, additional experiments were performed with mice fed normal chow. Mice in group 2 (Fv^+/+,ApoE^–/– [n=9], Fv^Q/+,ApoE^–/– [n=9], and Fv^Q/Q,ApoE^–/– [n=9]) were maintained on normal chow and euthanized at 34 weeks of age. As in group 1, there was no significant difference in aortic lesion area among the 3 different groups of mice (Figure 2a). Because alterations in coagulation might have a chronic, low-grade effect on atherosclerosis and only be apparent after a prolonged period, group 3 (Fv^+/+,ApoE^–/– [n=12], Fv^Q/+,ApoE^–/– [n=12], and Fv^Q/Q,ApoE^–/– [n=8]) was maintained on normal chow and euthanized at 52 weeks of age. In group 3, Fv^Q/Q,ApoE^–/– mice displayed significantly more aortic atherosclerosis than Fv^+/+,ApoE^–/– mice, whereas Fv^Q/+,ApoE^–/– mice had an intermediate phenotype (Figure 2a). Aortic plaques from Fv^Q/Q,ApoE^–/– mice (n=6) in group 3 also showed significantly more fibrin deposition compared with Fv^+/+,ApoE^–/– mice (n=10) (Figure 2b). A similar trend for fibrin deposition was also seen in group 2 between Fv^Q/Q,ApoE^–/– (n=8) and Fv^+/+,ApoE^–/– mice (n=6), but this difference did not reach statistical significance (Figure 2b). No differences in carotid artery atherosclerosis were noted among the groups (data not shown). There were no differences in cholesterol among the various genotypes in group 3 (Fv^+/+,ApoE^–/–=403±44, Fv^Q/+,ApoE^–/–=406±58, Fv^Q/Q,ApoE^–/–=449±61 mg/dL).

View larger version (55K): [in this window] [in a new window]   Figure 2. a–c, Analysis of atherosclerosis. a, Quantification of lesion surface area involving thoracic aorta in 19-, 34-, and 52-week-old mice. *P<0.02 compared with Fv+/+,ApoE–/– mice. HFC indicates high-fat chow. b, Fibrin(ogen) staining (red) of aortic atherosclerotic plaques from 34- and 52-week-old mice. Prominent focal staining is observed in 34-week-old FvQ/Q,ApoE–/– mouse, suggesting previous plaque disruption with hemorrhage and persistent fibrin. Bar=20 µm. c, Fibrin(ogen) score from aortic cross sections obtained from Fv+/+,ApoE–/– and FvQ/Q,ApoE–/– mice. *P<0.05.

	Discussion

Top Abstract Introduction Methods Results Discussion References

 
FVL has a prevalence of 2% to 7% in most European populations^18,19 and is the major known genetic risk factor for venous thrombosis in humans. The risk of arterial thrombosis and atherosclerotic vascular disease associated with the FVL mutation is controversial. The Physicians Health Study⁴ as well as the Copenhagen City Heart study⁹ found no association between heterozygosity for FVL and myocardial infarction. However, other studies have demonstrated increased myocardial infarction risk associated with FVL carriers.^5,7,8,20 Because the prevalence of the homozygous state is so rare, 17 subjects (0.2%) in the Copenhagen City Heart Study and 0 subjects from the Physicians Health Study analysis, the associated risk for arterial thrombotic complications is difficult to determine. Mice homozygous for FVL have been previously generated and develop normally on a C57BL/6J genetic background.¹³ Plasma from these mice is resistant to the anticoagulant effect of activated protein C, similar to that seen in humans.¹³ In the present study, we first sought to determine whether homozygosity for FVL leads to enhanced thrombosis after arterial injury. A well-established photochemical carotid injury model that causes thrombosis after oxidative injury was used to address this question. This type of injury likely plays an important role in the progression of vascular disease^21,22; however, as with any induced-thrombosis model, the injury required to elicit thrombosis may not replicate the conditions leading to spontaneous thrombosis. This model may be particularly advantageous because the injury occurs to the endothelial cell layer, which is followed by platelet and fibrin deposition.²³ We and others have previously demonstrated that this model is sensitive to genetic alterations in coagulation, fibrinolytic, and platelet pathways.^{15,17,24–26} In this model, homozygous FvL mice formed occlusive thrombi in a significantly shorter time than did the wild-type mice, whereas heterozygotes were intermediate. Because there are 2 distinct pools of factor V,¹² one or both pools could contribute to the prothrombotic phenotype in this model. Factor V released from the platelet appears to play an important role in hemostasis, as neonatal lethal hemorrhage in mice deficient in factor V can be rescued by a platelet factor V transgene¹²; however, the pool of factor V activity most affected by activated protein C may be circulating plasma factor V. It has been demonstrated that after platelet activation, platelet-derived factor V is resistant to inactivation by activated protein C.²⁷ Consistent with this finding, bone marrow transplantation between Fv^Q/Q and Fv^+/+ mice in the present study demonstrated that plasma FVL was the predominant pool responsible for the prothrombotic phenotype in this model.

To further explore the interaction of coagulation and atherogenesis, we analyzed the effect of the FVL mutation on the development of atherosclerosis in the ApoE-deficient mouse. We have previously demonstrated that heterozygosity for tissue factor pathway inhibitor, favoring thrombin generation and coagulation, promoted the development of atherosclerosis in the ApoE-deficient mouse model.¹⁷ We have also demonstrated that plasminogen activator inhibitor-1 deficiency is associated with reduced carotid atherosclerosis, presumably via enhanced fibrinolysis.²⁸ Consistent with these previous findings, we now demonstrate that mice homozygous for the procoagulant FVL mutation develop significantly more atherosclerosis than do wild-type controls. This effect was observed only in normal chow-fed mice at 52 weeks of age. The difference in atherosclerosis involved the aortic arch but not peripheral bifurcation sites, as we have previously described with other factors involved in coagulation and fibrinolysis.^17,28 It may be that there are vascular bed–specific effects of various factors involved in coagulation and fibrinolysis, depending on gene expression patterns.²⁹ This enhanced late atherosclerosis was associated with more fibrin(ogen) deposition in Fv^Q/Q mice, with many Fv^Q/Q mice showing intense focal fibrin deposits. This observation may relate to the importance of enhanced thrombin formation with fibrin deposition during the later stages of atherosclerosis, when thrombotic complications are observed in humans. It may also take a long time for the effects of alterations in coagulation on atherosclerosis to become apparent. Fibrin has been shown to affect the development of atherosclerosis in mice overexpressing an apo(a) transgene³⁰; however, another study that analyzed mice with combined fibrinogen and ApoE deficiency demonstrated that fibrin is not required for the development of atherosclerosis.³¹ Thus, the mechanism for the increased atherosclerosis observed in the current study may also relate to fibrin-independent activities of thrombin. Additional experiments will be required to clearly define the underlying mechanisms.

These studies indicate that homozygosity for the FVL mutation in the mouse leads to enhanced arterial thrombosis and atherosclerosis. In addition, the prothrombotic phenotype observed after arterial injury appears to result from plasma-derived FVL. This may have important implications with regard to potential therapies designed to reverse the prothrombotic phenotype of patients with the FVL mutation. For example, it may be possible to reduce thrombophilia due to FVL by selectively targeting plasma factor V while still maintaining physiological hemostasis.

	Acknowledgments

 
This work was supported by grant PO1 HL057346 (Drs Eitzman and Ginsburg). Dr Ginsburg is a Howard Hughes Investigator. Dr Eitzman is the recipient of an Established Investigator Award from the American Heart Association. Dr Westrick is the recipient of an American Heart Association predoctoral award.

	References

Top Abstract Introduction Methods Results Discussion References

 

1. Svensson PJ. Resistance to activated protein C as a basis for venous thrombosis. N Engl J Med. 1994; 330: 517–522.[Abstract/Free Full Text]
   
2. Griffin JH, Evatt B, Wideman C, Fernandez JA. Anticoagulation protein C pathway defective in majority of thrombophilic patients. Blood. 1993; 82: 1989–1993.[Abstract/Free Full Text]
   
3. Koster T, Rosendaal FR, de Ronde H, Briet E, Vandenbroucke JP. Venous thrombosis due to poor anticoagulant response to activated protein C. Lancet. 1993; 342: 1503–1506.[CrossRef][Medline] [Order article via Infotrieve]
   
4. Ridker PM, Hennekens CH, Lindpaintner K, Stampfer MJ, Eisenberg PR, Miletich JP. Mutation in the gene coding for coagulation factor V and the risk of myocardial infarction, stroke, and venous thrombosis in apparently healthy men [see comments]. N Engl J Med. 1995; 332: 912–17.[Abstract/Free Full Text]
   
5. Van de Water NS, French JK, Lund M, Hyde TA, White HD, Browett PJ. Prevalence of factor V Leiden and prothrombin variant G20210A in patients age <50 years with no significant stenoses at angiography three to four weeks after myocardial infarction. J Am Coll Cardiol. 2000; 36: 717–722.[Abstract/Free Full Text]
   
6. Makris M, Preston FE, Beauchamp NJ, Cooper PC, Daly ME, Hampton KK, Bayliss P, Peake IR, Miller GJ. Co-inheritance of the 20210A allele of the prothrombin gene increases the risk of thrombosis in subjects with familial thrombophilia. Thromb Haemost. 1997; 78: 1426–1429.[Medline] [Order article via Infotrieve]
   
7. Inbal A, Freimark D, Modan B, Chetrit A, Matetzky S, Rosenberg N, Dardik R, Baron Z, Seligsohn U. Synergistic effects of prothrombotic polymorphisms and atherogenic factors on the risk of myocardial infarction in young males. Blood. 1999; 2186–2190.
   
8. Rosendaal FR, Siscovick DS, Schwartz SM, Beverly RK, Psaty BM, Longstreth WT Jr, Raghunathan TE, Koepsell TD, Reitsma PH. Factor V Leiden (resistance to activated protein C) increases the risk of myocardial infarction in young women [see comments]. Blood. 1997; 89: 2817–2821.[Abstract/Free Full Text]
   
9. Juul K, Tybjaerg-Hansen A, Steffensen R, Kofoed S, Jensen G, Nordestgaard BG. Factor V Leiden: the Copenhagen City Heart Study and 2 meta-analyses. Blood. 2002; 100: 3–10.[Abstract/Free Full Text]
   
10. Camire RM, Pollak ES, Kaushansky K, Tracy PB. Secretable human platelet-derived factor V originates from the plasma pool. Blood. 1998; 92: 3035–3041.[Abstract/Free Full Text]
    
11. Yang TL, Pipe SW, Yang A, Ginsburg D. Biosynthetic origin and functional significance of murine platelet factor V. Blood. 2003; 102: 2851–2855.[Abstract/Free Full Text]
    
12. Sun H, Yang TL, Yang A, Wang X, Ginsburg D. The murine platelet and plasma factor V pools are biosynthetically distinct and sufficient for minimal hemostasis. Blood. 2003; 102: 2856–2861.[Abstract/Free Full Text]
    
13. Cui J, Eitzman DT, Westrick RJ, Christie PD, Xu Z, Yang A, Purkayastha A, Yang TL, Metz AL, Gallagher KP, Tyson J, Rosenberg RD, Ginsburg D. Spontaneous thrombosis in mice carrying the factor V Leiden mutation. Blood. 2000; 96: 4222–4226.[Abstract/Free Full Text]
    
14. Sjoland H, Eitzman DT, Gordon D, Westrick RJ, Nabel EG, Ginsburg D. Atherosclerosis progression in LDL receptor–deficient and apolipoprotein E–deficient mice is independent of genetic alterations in plasminogen activator inhibitor-1. Arterioscler Thromb Vasc Biol. 2000; 20: 846–852.[Abstract/Free Full Text]
    
15. Eitzman DT, Westrick RJ, Nabel EG, Ginsburg D. Plasminogen activator inhibitor-1 and vitronectin promote vascular thrombosis in mice. Blood. 2000; 95: 577–580.[Abstract/Free Full Text]
    
16. Eitzman DT, Bodary PF, Shen Y, Khairallah CG, Wild SR, Abe A, Shaffer-Hartman J, Shayman JA. Fabry disease in mice is associated with age-dependent susceptibility to vascular thrombosis. J Am Soc Nephrol. 2003; 14: 298–302.[Abstract/Free Full Text]
    
17. Westrick RJ, Bodary PF, Xu Z, Shen YC, Broze GJ, Eitzman DT. Deficiency of tissue factor pathway inhibitor promotes atherosclerosis and thrombosis in mice. Circulation. 2001; 103: 3044–3046.[Abstract/Free Full Text]
    
18. Zoller B, Dahlback B. Linkage between inherited resistance to activated protein C and factor V gene mutation in venous thrombosis. Lancet. 1994; 343: 1536–1538.[CrossRef][Medline] [Order article via Infotrieve]
    
19. Voorberg J, Roelse J, Koopman R, Buller H, Berends F, ten Cate J, Mertens K, van Mourik J. Association of idiopathic venous thromboembolism with single point-mutation at Arg⁵⁰⁶ of factor V. Lancet. 1994; 343: 1535–1536.[CrossRef][Medline] [Order article via Infotrieve]
    
20. Makris TK, Krespi PG, Hatzizacharias AN, Gialeraki AE, Anastasiadis G, Triposkiadis FK, Mandalaki T, Kyriakidis MK. Resistance to activated protein C and FV Leiden mutation in patients with a history of acute myocardial infarction or primary hypertension. Am J Hypertens. 2000; 13 (pt 1): 61–65.[CrossRef][Medline] [Order article via Infotrieve]
    
21. Vandeplassche G, Bernier M, Kusama BM. Singlet oxygen and myocardial injury: ultrastructural, cytochemical and electrocardiographic consequences of photoactivation of rose bengal. J Mol Cell Cardiol. 1990; 22: 287–301.[CrossRef][Medline] [Order article via Infotrieve]
    
22. White CR, Chang LY, Crapo J, Ku D, Gianturco SH, Gore J, Freeman BA. Superoxide and peroxynitrite in atherosclerosis. Proc Natl Acad Sci U S A. 1995; 91: 1044–1048.
    
23. Matsuno H, Uematsu T, Nagashima S, Nakashima M. Photochemically induced thrombosis model in rat femoral artery and evaluation of effects of heparin and tissue-type plasminogen activator with use of this model. J Pharmacol Methods. 1991; 25: 303–318.[CrossRef][Medline] [Order article via Infotrieve]
    
24. He L, Vicente CP, Westrick RJ, Eitzman DT, Tollefsen DM. Heparin cofactor II inhibits arterial thrombosis after endothelial injury. J Clin Invest. 2002; 109: 213–219.[CrossRef][Medline] [Order article via Infotrieve]
    
25. Eitzman DT, Westrick RJ, Xu Z, Tyson J, Ginsburg D. Hyperlipidemia promotes thrombosis after injury to atherosclerotic vessels in apolipoprotein E–deficient mice. Arterioscler Thromb Vasc Biol. 2000; 20: 1831–1834.[Abstract/Free Full Text]
    
26. Bodary PF, Westrick RJ, Wickenheiser KJ, Shen Y, Eitzman DT. Effect of leptin on arterial thrombosis following vascular injury in mice. JAMA. 2002; 287: 1706–1709.[Abstract/Free Full Text]
    
27. Camire RM, Kalafatis M, Simioni P, Girolami A, Tracy PB. Platelet-derived factor Va/Va Leiden cofactor activities are sustained on the surface of activated platelets despite the presence of activated protein C. Blood. 1998; 91: 2818–2829.[Abstract/Free Full Text]
    
28. Eitzman DT, Westrick RJ, Xu Z, Tyson J, Ginsburg D. Plasminogen activator inhibitor-1 deficiency protects against atherosclerosis progression in the mouse carotid artery. Blood. 2000; 96: 4212–4215.[Abstract/Free Full Text]
    
29. Rosenberg RD, Aird WC. Mechanisms of disease: vascular-bed–specific hemostasis and hypercoagulable states. N Engl J Med. 1999; 340: 1555–1564.[Free Full Text]
    
30. Lou XJ, Boonmark NW, Horrigan FT, Degen JL, Lawn RM. Fibrinogen deficiency reduces vascular accumulation of apolipoprotein(a) and development of atherosclerosis in apolipoprotein(a) transgenic mice. Proc Natl Acad Sci U S A. 1998; 95: 12591–12595.[Abstract/Free Full Text]
    
31. Xiao Q, Danton MJ, Witte DP, Kowala MC, Valentine MT, Degen JL. Fibrinogen deficiency is compatible with the development of atherosclerosis in mice. J Clin Invest. 1998; 101: 1184–1194.[Medline] [Order article via Infotrieve]
    

Related Articles:

Issue Highlights
Circulation 2005 111: 1729. [Full Text]

Another Lesson From the Factor V Leiden Mouse: Thrombin Generation Drives Arterial Disease

Steven R. Lentz
Circulation 2005 111: 1733-1734. [Full Text]

This article has been cited by other articles:

				E. M. deGoma, R. L. deGoma, and D. J. Rader Beyond high-density lipoprotein cholesterol levels evaluating high-density lipoprotein function as influenced by novel therapeutic approaches. J. Am. Coll. Cardiol., June 10, 2008; 51(23): 2199 - 2211. [Abstract] [Full Text] [PDF]

				R. J. Westrick, M. E. Winn, and D. T. Eitzman Murine Models of Vascular Thrombosis Arterioscler. Thromb. Vasc. Biol., October 1, 2007; 27(10): 2079 - 2093. [Abstract] [Full Text] [PDF]

				K. K. Koh and B.-K. Yoon Controversies regarding hormone therapy: Insights from inflammation and hemostasis Cardiovasc Res, April 1, 2006; 70(1): 22 - 30. [Abstract] [Full Text] [PDF]

				S. R. Lentz Another Lesson From the Factor V Leiden Mouse: Thrombin Generation Drives Arterial Disease Circulation, April 12, 2005; 111(14): 1733 - 1734. [Full Text] [PDF]

This Article Abstract Full Text (PDF) All Versions of this Article: 111/14/1822    most recent 01.CIR.0000160854.75779.E8v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Eitzman, D. T. Articles by Ginsburg, D. Search for Related Content PubMed PubMed Citation Articles by Eitzman, D. T. Articles by Ginsburg, D. Pubmed/NCBI databases Gene GEO Profiles HomoloGene UniGene Substance via MeSH Related Collections Arterial thrombosis Coagulation Thrombin Other Vascular biology Animal models of human disease Pathophysiology Genetically altered mice Related Articles